Experimental immune cell therapy targets Hard-to-Treat cancers
NCT ID NCT07563972
First seen May 15, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This early-phase study tests the safety of a new treatment made from immune cells (macrophages) that are reprogrammed to fight cancer. The treatment is injected directly into tumors in adults aged 18-65 with advanced solid tumors who have no other options. The goal is to see if it is safe and tolerable, and to measure any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.